Doc #118 — Anesthesia Alternatives: Maintaining Surgical Pain Control Without Imports

---

RECOMMENDED ACTIONS

Phase 1 — First two weeks [IMMEDIATE to URGENT]

1. Inventory all anaesthetic agents nationwide. Every hospital pharmacy, every anaesthetic department store, every veterinary practice, every distributor warehouse. Include: sevoflurane, isoflurane, desflurane, propofol, thiopentone, ketamine, suxamethonium, rocuronium, atracurium, cisatracurium, lidocaine (all formulations), bupivacaine, ropivacaine, levobupivacaine, midazolam, fentanyl, alfentanil, remifentanil, morphine. [Phase 1 — IMMEDIATE]

2. Issue national anaesthetic conservation guidelines. Mandate low-flow anaesthesia circuits for all volatile agent use. Mandate regional/local anaesthesia as first-line for all suitable cases. Reserve general anaesthesia for cases where regional anaesthesia is contraindicated or insufficient. [Phase 1 — IMMEDIATE]

3. Integrate veterinary anaesthetic stocks. Inventory ketamine, lidocaine, xylazine, and other agents in veterinary supply. Establish a review board (anaesthetist + veterinarian + pharmacist) to assess human usability of veterinary formulations. [Phase 1 — URGENT]

4. Establish national ketamine registry. Every vial and bottle tracked centrally. Allocate by clinical priority. [Phase 1 — URGENT]

Phase 1 — First three months [HIGH PRIORITY]

5. Begin retraining programme for ether anaesthesia. Identify anaesthetists with any historical exposure. Obtain or reproduce instructional texts (Macintosh & Mushin’s Physics for the Anaesthetist, WHO anaesthesia manuals). Begin simulation-based training. [Phase 1]

6. Begin retraining programme for expanded regional anaesthesia. All anaesthetists trained in spinal anaesthesia for the widest possible range of procedures. Refresh nerve block skills. Ensure ultrasound-guided regional anaesthesia is standardised. [Phase 1]

7. Commission drawover vaporiser fabrication. Provide EMO-type vaporiser specifications to NZ machine shops (Doc #91). Begin prototype production. Target: at least one functional drawover vaporiser per surgical centre within 6 months. [Phase 1]

8. Secure sulfuric acid stocks for ether production. Identify all existing NZ sulfuric acid stock — industrial, laboratory, battery acid. Reserve a portion for pharmaceutical ether synthesis. Begin planning for local sulfuric acid production (Doc #113). [Phase 1]

Phase 2 — Months 6–24 [PRIORITY to STRATEGIC]

9. Begin pilot-scale ether production at a suitable chemistry laboratory (University of Auckland, University of Otago, or Callaghan Innovation). Produce test batches. Establish quality control protocols (peroxide testing, acidity, water content, purity). [Phase 2]

10. Clinical validation of locally produced ether. First use in supervised, non-critical anaesthetics with modern agents immediately available as backup. Build confidence in product quality and anaesthetic technique. [Phase 2]

11. Scale ether production to meet projected clinical demand (10–60 litres per year — see Section 4.5). Establish at least two production sites for redundancy. [Phase 2]

12. Establish procaine production pathway if coal tar distillation infrastructure develops (Doc #51, Section 3.6). This is a longer-term goal — years, not months. [Phase 2–3]

---

ECONOMIC JUSTIFICATION

Labour requirements

Ether production: 2–5 FTE skilled personnel (chemists or chemical technicians) for production and quality control. This is a small allocation relative to NZ’s approximately 2,000–3,000 chemists and chemical technicians, though competition for this workforce from other recovery-critical chemical production programmes (Doc #113, Doc #119) must be considered.³

Vaporiser fabrication: 1–3 FTE machinist-months per unit (Doc #91). Approximately 20–30 drawover vaporisers are needed to equip NZ’s approximately 20–25 public surgical centres plus selected private and rural facilities.⁴ Total fabrication effort: approximately 5–15 person-months.

Retraining: All NZ anaesthetists (~550 specialist anaesthetists, plus approximately 200 anaesthetic registrars and GP anaesthetists in rural practice) require retraining.⁵ This is an educational investment that costs clinical time (estimated 40–80 hours per practitioner over 6–12 months) but does not require dedicated production labour.

Total direct labour for the anaesthesia transition programme: Approximately 10–20 person-years over the first 3 years, including production, quality control, equipment fabrication, and training coordination. This is modest relative to the capability it preserves.

Comparison with alternatives

Alternative 1: Do nothing — use modern agents until exhausted, then stop performing surgery requiring anaesthesia.

This is not a viable option. Surgery without anaesthesia means death from conditions that are survivable with surgery: appendicitis, strangulated hernia, compound fractures, caesarean sections, wound debridement. The mortality cost of losing surgical capability is estimated at 2,000–5,000 avoidable deaths per year, based on NZ’s emergency surgical volume and the historical mortality of untreated surgical conditions.⁶

Alternative 2: Rely solely on regional anaesthesia and ketamine.

Better than nothing. Regional anaesthesia covers a substantial fraction of surgical procedures (estimated 40–60% of the emergency surgical workload). Ketamine covers much of the remainder. But regional anaesthesia requires local anaesthetic drugs (finite) and ketamine stocks are also finite. Without ether production, NZ eventually exhausts all anaesthetic capability. Ether is the only general anaesthetic NZ can produce locally.

Alternative 3: Invest in ether production and comprehensive anaesthetic transition (this document).

Preserves general anaesthetic capability indefinitely, supplemented by regional techniques and ketamine during the bridge period. The production investment is small. The training investment is moderate. The capability preserved is essential.

Breakeven

Immediate. The first litre of quality-controlled ether produced locally represents a capability NZ permanently lacks without the programme. There is no point at which the investment fails to justify itself, because the alternative is no general anaesthesia once modern stocks are depleted.

---

1. NZ’S CURRENT ANAESTHETIC CAPABILITY

1.1 The workforce

NZ has approximately 550 specialist anaesthetists (Fellows of the Australian and New Zealand College of Anaesthetists, FANZCA), concentrated in the major centres: Auckland (approximately 150–180), Wellington (approximately 60–80), Christchurch (approximately 50–70), Hamilton (approximately 30–40), and Dunedin (approximately 20–30), with the remainder distributed across regional and rural hospitals.⁷ In addition, approximately 100–200 GP anaesthetists provide anaesthesia services in smaller rural hospitals — a system relatively unique to NZ and Australia, where rural distances make specialist coverage impractical.⁸

Strengths: NZ’s anaesthetic workforce is highly trained by international standards. FANZCA training is 5 years of specialist postgraduate education. NZ anaesthetists are skilled in regional anaesthesia, airway management, resuscitation, and perioperative medicine.

Weakness for the recovery scenario: No NZ anaesthetist in active practice has clinical experience with ether anaesthesia. Ether was phased out of NZ clinical practice in the 1970s–1980s with the introduction of halothane and then enflurane/isoflurane/sevoflurane.⁹ Some senior anaesthetists (those who trained before the mid-1980s) may have observed or administered ether during training, but this is residual and decades old. The skill must be relearned, not remembered.

1.2 Infrastructure

NZ has approximately 80–100 operating theatres across its public hospital network, plus additional theatres in private surgical facilities.¹⁰ Each theatre is equipped with a modern anaesthetic machine (predominantly Draeger and GE Healthcare brands in NZ), which delivers volatile agents through calibrated vaporisers, provides mechanical ventilation, monitors oxygen/carbon dioxide/agent concentration, and integrates patient monitoring (ECG, pulse oximetry, blood pressure, temperature).

What survives: Under the baseline scenario (grid continues — see plan baseline), anaesthetic machines continue to function. Monitoring equipment continues to function. Suction, operating lights, and theatre ventilation continue. The infrastructure problem is not the machines — it is the consumable agents that the machines deliver.

What fails eventually: Electronic monitoring components will degrade and become irreplaceable (Phase 4–5). Vaporisers calibrated for modern agents cannot deliver ether safely. Soda lime (carbon dioxide absorbent in circle breathing circuits) is imported and finite — exhaustion of soda lime stocks forces a switch to non-rebreathing circuits, which increases volatile agent consumption. Disposable breathing circuit components (tubing, filters, masks) eventually exhaust.

1.3 Agent stocks and depletion timeline

The depletion estimates below are based on NZ’s pre-event surgical volume (~200,000 anaesthetics per year)¹¹, reduced by approximately 50–70% under post-event conditions (elective surgery suspended, reduced trauma from reduced road traffic, but increased wound and infection surgery). Post-event anaesthetic volume is estimated at 60,000–100,000 per year, declining as surgical consumables deplete (Doc #117). Conservation measures (low-flow circuits, regional anaesthesia shift) further reduce volatile agent consumption per case.

Agent	NZ stock (estimate)	Post-event consumption	Estimated duration	Notes
Sevoflurane	500–2,000 litres across all sources	200–800 L/year with conservation	1–3 years	Primary volatile agent in NZ. Low-flow technique reduces consumption 50–75%12
Isoflurane	50–300 litres	Minimal — used as sevoflurane backup	1–3 years as supplement	Cheaper, less pleasant for patients. Stock smaller because NZ shifted to sevoflurane
Propofol	1,000–5,000 ampoules/vials	Used for induction; 2–5 mL per case	6–24 months	Lipid emulsion — limited shelf-life extension. Some degradation risk
Ketamine	200–1,000 vials (human) + substantial veterinary stock	Variable — depends on how aggressively it is deployed	2–5+ years with veterinary integration	Most valuable bridging agent. Long shelf life as solid or concentrated solution
Thiopentone	Small stocks — largely superseded	Backup induction agent	Months	Reconstituted from powder — reasonable shelf life as powder
Lidocaine	5,000–20,000 ampoules/vials across all formulations	High — used for local infiltration, nerve blocks, spinal (off-label), cardiac arrhythmia	1–3 years	Workhorse local anaesthetic. Multiple formulations and concentrations
Bupivacaine	1,000–5,000 ampoules	Used for spinal and epidural — small volumes per case (1–3 mL for spinal)	2–5 years for spinal use	If reserved for spinal/epidural, lasts much longer than if used for field blocks
Ropivacaine	500–3,000 ampoules	Used for nerve blocks, epidurals	1–3 years	Similar to bupivacaine but with lower cardiac toxicity profile
Midazolam	1,000–5,000 ampoules	Sedation, anxiolysis, ketamine co-administration	1–3 years	Valuable for managing ketamine emergence phenomena
Fentanyl	2,000–10,000 ampoules	Intraoperative analgesia — small doses per case	1–3 years	Potent; small volumes used. Controlled substance
Morphine	Moderate stocks (tablets and injectable)	Surgical analgesia, palliative care	2–5 years (tablets extend well per SLEP)	Injectable forms have moderate shelf-life extension
Soda lime	500–2,000 kg	0.5–2 kg per anaesthetic with circle circuit	6–24 months	When exhausted, must switch to non-rebreathing circuits (higher agent consumption) or drawover systems
Neuromuscular blockers (rocuronium, atracurium, suxamethonium)	2,000–10,000 vials across types	Used for intubation and surgical relaxation	1–3 years	Atracurium requires cold storage. Suxamethonium requires cold storage. Rocuronium is most stable

Assumption: These stock estimates are approximate and based on general NZ hospital procurement patterns and supply chain data. The actual figures require the immediate inventory described in Action 1. The estimates may be wrong by a factor of 2 in either direction.

Key observation: The depletion timeline is 1–3 years for most agents, with ketamine and bupivacaine (if strictly reserved for spinal use) potentially lasting longer. This means that by Phase 2 (Years 1–3), NZ must have functional alternatives or accept a dramatic reduction in surgical capability.

---

2. CONSERVATION: MAKING EXISTING STOCKS LAST

2.1 Low-flow anaesthesia

The single most effective conservation measure for volatile agents is low-flow anaesthetic technique, which most NZ anaesthetists already know but do not consistently practise because, under normal conditions, the cost of sevoflurane does not justify the additional monitoring attention required.

How it works: In a standard semi-open breathing circuit, fresh gas flows of 2–6 L/min carry volatile agent to the patient, and exhaled gas (still containing substantial agent) is vented to the scavenging system. In a low-flow or minimal-flow circuit (fresh gas flow 0.3–0.5 L/min), a circle system with soda lime absorbs carbon dioxide, and most of the exhaled agent is re-inhaled. Agent consumption drops by 50–75%.¹³

Requirements: A modern anaesthetic machine with a circle breathing circuit and soda lime absorber (standard in all NZ operating theatres), an agent analyser to monitor inspired and expired concentrations (standard in NZ), and an anaesthetist comfortable with the technique.

Limitation: Low-flow technique depends on soda lime, which is itself an imported consumable. When soda lime stocks are exhausted, low-flow circle circuits cease to function and the conservation benefit is lost. This creates a perverse dynamic: the most effective conservation strategy for volatile agents accelerates depletion of another critical consumable. The optimal approach is to use low-flow circuits while soda lime remains available, extending volatile agent stocks as far as possible, and transition to drawover ether systems before soda lime runs out — not after.

2.2 Shift from general to regional anaesthesia

The second most effective conservation strategy is performing more surgery under regional or local anaesthesia, eliminating the need for volatile agents, propofol, and muscle relaxants for those cases.

Procedures suitable for spinal anaesthesia (injection of local anaesthetic into the cerebrospinal fluid):¹⁴

• Caesarean section (already the standard anaesthetic for elective and most emergency caesarean sections in NZ)
• Lower limb surgery: fracture fixation, amputation, soft tissue procedures
• Lower abdominal surgery: appendicectomy, hernia repair, bowel surgery below the umbilicus
• Urological surgery: bladder, prostate (in peacetime, this was mainly elective; under recovery conditions, urgent urological surgery would be the indication)
• Gynaecological surgery below the umbilicus

Volume of local anaesthetic per spinal: 1.5–3.5 mL of 0.5% bupivacaine (heavy) — approximately 7.5–17.5 mg of bupivacaine per case. This is a fraction of the volume required for epidural or field-block anaesthesia (which may use 20–40 mL of local anaesthetic). If bupivacaine is reserved exclusively for spinal use, a stock of 5,000 ampoules at 4 mL each (20,000 mL total) could provide approximately 5,700–13,000 spinal anaesthetics — potentially covering 3–7 years of post-event lower-body surgery.¹⁵

Procedures suitable for peripheral nerve blocks:

• Upper limb surgery (brachial plexus block): fracture fixation, amputation, wound debridement
• Lower limb surgery (femoral/sciatic block): as alternative or supplement to spinal
• Chest wall procedures (intercostal blocks): rib fracture analgesia, chest drain insertion

Nerve blocks require larger volumes of local anaesthetic than spinal (10–40 mL per block) but avoid the haemodynamic effects of spinal anaesthesia and can be titrated. Ultrasound-guided blocks, practised by most NZ anaesthetists, improve success rates and reduce local anaesthetic volumes by improving needle placement accuracy.¹⁶

Procedures suitable for local infiltration:

• Wound repair, laceration suturing
• Abscess incision and drainage
• Skin lesion excision
• Central line insertion, chest drain insertion, and other bedside procedures
• Minor orthopaedic procedures

Local infiltration uses lidocaine (typically 1–2%, 5–20 mL per case). This is the most local-anaesthetic-intensive technique per unit of surgery and should be used only when spinal or nerve block is not appropriate.

2.3 Ketamine conservation strategy

Ketamine is NZ’s most strategically important anaesthetic agent because it bridges the gap between modern anaesthetic depletion and local ether production. Conservation principles:

Reserve ketamine for cases where its unique properties are essential:

• Anaesthesia where no anaesthetic machine is available (field surgery, rural settings, mass casualty)
• Patients where spinal anaesthesia is contraindicated (hypovolaemic shock — spinal causes dangerous hypotension; coagulopathy; patient refusal; spinal deformity)
• Paediatric anaesthesia (children tolerate ketamine well and are technically challenging for spinal anaesthesia)
• Burn debridement and dressing changes (ketamine’s analgesic properties are particularly valuable)
• Short procedures where ether induction would be disproportionately slow

Do not use ketamine where regional anaesthesia is adequate. A spinal anaesthetic using 2 mL of bupivacaine preserves a dose of ketamine for a case where ketamine is the only option.

Veterinary ketamine integration: NZ’s veterinary supply of ketamine is substantial — ketamine is one of the most widely used veterinary anaesthetic agents, used in every veterinary practice and in significant quantities by equine, farm animal, and zoo veterinarians.¹⁷ Veterinary ketamine is chemically identical to human ketamine (ketamine hydrochloride in aqueous solution, typically 100 mg/mL). The formulation is the same. The regulatory distinction between human and veterinary labelling is exactly that — a label. A pharmacist and veterinarian review should confirm formulation equivalence for specific products, but the default assumption is that veterinary ketamine is usable in humans.¹⁸

Ketamine limitations that affect planning:

• Emergence phenomena: Approximately 10–30% of adult patients experience vivid hallucinations, dysphoria, or agitation on emergence from ketamine anaesthesia. This is reduced by co-administration of midazolam (0.03–0.05 mg/kg) or diazepam, but both of these are finite. Without benzodiazepine co-administration, ketamine emergence is manageable but unpleasant and sometimes frightening for patients and staff.¹⁹
• Raised intracranial pressure: Ketamine is traditionally considered contraindicated in head injury, though recent evidence suggests this concern may be overstated in patients with controlled ventilation. For planning purposes, head injury patients should receive alternative anaesthesia where possible.²⁰
• Raised intraocular pressure: Contraindicated for open eye injury surgery.
• Nausea and vomiting: Less than ether but still significant.
• Secretions: Ketamine increases salivary and bronchial secretions. Atropine or glycopyrrolate co-administration mitigates this — both are finite but typically available in NZ hospital stock.
• Abuse potential: Ketamine is a controlled drug with recreational abuse potential. Under rationing, secure storage and dispensing are essential.

---

3. ETHER: THE LOCAL PRODUCTION PATHWAY

3.1 Why ether

Diethyl ether is the only general anaesthetic agent NZ can produce from locally available materials. This is a constraint. The modern volatile agents (sevoflurane, isoflurane, desflurane) are fluorinated hydrocarbons requiring industrial fluorine chemistry that NZ will not possess for decades. Propofol requires phenol and isopropyl alcohol — petrochemical derivatives. Thiopentone requires barbituric acid synthesis from malonic acid and urea, with sulfur incorporation — achievable organic chemistry but dependent on precursor chemicals NZ does not have. Chloroform is a secondary option (Section 3.3 below) but has a narrower safety margin and hepatotoxicity risk.²¹

Ether’s chemistry is straightforward: ethanol + sulfuric acid catalyst at 140°C yields diethyl ether + water. NZ has ethanol (fermentation — abundant feedstock from grain, sugar, fruit waste). NZ can produce sulfuric acid (from geothermal sulfur deposits in the Taupo Volcanic Zone — Doc #113). The reaction is well-characterised, requires standard laboratory or small-scale industrial equipment, and has been performed continuously since the 1840s.²²

3.2 Production process

Step 1 — Ethanol preparation. Ethanol for ether synthesis should be at least 95% concentration (standard distillation achieves this). Absolute (anhydrous) ethanol is preferred but not essential — the water content of 95% ethanol is carried through and removed in subsequent purification steps. NZ’s distilling industry, brewing industry, and the bioethanol sector provide both equipment and expertise for producing distilled ethanol from grain, sugar beet, molasses, or fruit waste.²³

Step 2 — Reaction. In a round-bottom flask or reaction vessel (glass or glass-lined — sulfuric acid corrodes most metals), concentrated sulfuric acid is heated to 140°C. Ethanol is added slowly and continuously. At this temperature, the acid catalyses dehydration of ethanol to diethyl ether:

2 C₂H₅OH → C₂H₅OC₂H₅ + H₂O

The ether (boiling point 34.6°C) distils off as vapour, is passed through a condenser (water-cooled), and collects as a liquid. Temperature control is critical: below 130°C, the reaction is too slow; above 150°C, ethylene (a gas) is preferentially produced instead of ether.²⁴

Step 3 — Washing. The crude distillate contains ether, water, ethanol, and traces of sulfuric acid and sulfur dioxide. Purification sequence:

1. Wash with water (separatory funnel) to remove ethanol and most acid. Ether is only slightly soluble in water (6.9 g/100 mL at 20°C) — the bulk partitions into the organic (ether) layer.
2. Wash with dilute sodium hydroxide solution (5–10%) to neutralise residual acid. This step is essential — acidic ether corrodes metal containers and is irritating to airways.
3. Wash again with water to remove sodium hydroxide.
4. Dry over anhydrous calcium chloride or anhydrous sodium sulfate (24 hours minimum) to remove residual water.
5. Redistil, collecting the fraction boiling at 34–35°C and discarding the first and last fractions (which contain impurities and higher-boiling byproducts).²⁵

Step 4 — Stabilisation. Ether exposed to air and light forms organic peroxides (diethyl ether peroxide), which are shock-sensitive explosives. This is not a theoretical concern — ether peroxide explosions have killed laboratory workers.²⁶ Stabilisation measures:

• Add 5–10 ppm butylated hydroxytoluene (BHT) as an antioxidant, if available from NZ’s food industry stocks
• Alternatively, place clean copper wire or copper gauze in the storage container — copper catalyses peroxide decomposition
• Store in dark, amber glass bottles filled as completely as possible (minimising headspace/air contact)
• Store in a cool, dark location away from any heat source or ignition source
• Label with production date. Use within 6–12 months. Test for peroxides before any use after storage (see Section 3.3)

Step 5 — Storage. Ether must be stored in a dedicated, well-ventilated, explosion-proof magazine separate from the operating theatre. Ether vapour is 2.6 times denser than air and accumulates at floor level, creating invisible explosive atmospheres. No electrical switches, static-generating equipment, or ignition sources of any kind within the storage area.²⁷

3.3 Quality control — the critical step

Impure ether is dangerous. Peroxide-containing ether can explode. Acidic ether irritates airways and damages lung tissue. Ether contaminated with ethanol produces unpredictable anaesthetic depth. Quality control is the difference between a functional anaesthetic and a patient injury.

Required tests before any clinical use:

Test	What it detects	Method	Pass criterion
Peroxide test	Explosive peroxides from air exposure	Add 1 mL ether to acidified potassium iodide solution (1% KI in 10% H₂SO₄). Yellow or brown colour indicates peroxides. Alternatively: commercial peroxide test strips if available	No colour change (no peroxides detected). If positive, the ether must be treated with ferrous sulfate solution or redistilled before use — never use peroxide-positive ether28
Acidity/alkalinity	Residual sulfuric acid or sodium hydroxide from inadequate washing	Shake ether with equal volume of water. Test the water layer with pH paper or litmus	pH 5–7 (near neutral). Strongly acidic or alkaline ether must be rewashed
Water content	Excess water — causes turbidity and variable potency	Visual inspection (clear, not cloudy). Shake with anhydrous copper sulfate (white when dry, turns blue with water)	Clear ether. Copper sulfate remains white or very pale blue
Residual ethanol	Ethanol contamination — alters anaesthetic properties	Add a few drops of ether to a watch glass and let evaporate. Ethanol-contaminated ether leaves a residue with alcohol odour. More precisely: specific gravity measurement (pure ether SG = 0.713 at 20°C; ethanol contamination raises SG)29	No residue, no alcohol smell. SG within 0.710–0.720
Non-volatile residue	High-boiling impurities, degradation products	Evaporate 50 mL ether in a clean glass dish. Weigh any residue	Less than 1 mg residue per 50 mL
Odour	Characteristic sweet ether smell — off-odours indicate contamination	Trained assessor	Clean, sweet, characteristic. No pungent, acrid, or unusual odours

A basic chemistry laboratory can perform all of these tests. The reagents (potassium iodide, sulfuric acid, copper sulfate, pH paper) are available in NZ university and hospital laboratories. The requirement is not sophisticated equipment but disciplined adherence to testing protocols and the willingness to reject a batch that fails any test. In a production programme under pressure to supply operating theatres, the temptation to cut corners on quality control is the greatest danger.³⁰

3.4 Dependency chain

Ether production depends on:

1. Ethanol — NZ can produce from fermented grain, sugar, or fruit waste. Distillation infrastructure exists. [Available]
2. Sulfuric acid — NZ does not currently produce. Raw material (elemental sulfur from geothermal sources in the Taupo Volcanic Zone) is available. Production by the contact process or lead chamber process is a significant but feasible industrial chemistry project (Doc #113). Sulfuric acid is not consumed in ether synthesis — it is a catalyst, recoverable and reusable — so a small quantity goes a long way. However, ether production cannot begin until at least a small quantity of concentrated sulfuric acid is available.³¹
3. Glassware or glass-lined reaction vessels — NZ university and hospital laboratories have glassware. Glass-lined industrial vessels may need to be fabricated (Doc #98 — glass production). Standard borosilicate laboratory glass (Pyrex or equivalent) is suitable for small-scale production.
4. Condenser and distillation apparatus — standard chemistry equipment. Available in NZ laboratories. For larger-scale production, a copper or stainless steel condenser can be fabricated (Doc #70).
5. Stabilisers — BHT from food industry stocks, or copper wire (abundant — Doc #70).
6. Quality control reagents — potassium iodide, copper sulfate, pH indicators. Available in NZ laboratories. Finite but consumed in very small quantities per test.

The binding constraint is sulfuric acid. Until Doc #113 delivers sulfuric acid — even in small laboratory quantities — ether production cannot proceed. This makes sulfuric acid production a critical upstream dependency for the entire anaesthesia transition programme.

Workaround if sulfuric acid is delayed: Phosphoric acid can substitute as a dehydration catalyst, though at lower efficiency (requiring higher temperatures of 180–200°C vs. 140°C, yielding approximately 20–40% less ether per batch due to increased ethylene byproduct formation) and with more byproduct contamination requiring additional purification steps.³² NZ may hold phosphoric acid stocks in the fertiliser industry (Ravensdown and Ballance Agri-Nutrients use it in superphosphate production) and food industry (food-grade phosphoric acid). This is not the preferred route, but it provides a fallback if sulfuric acid production takes longer than planned.

3.5 Production scale

How much ether does NZ need?

A single surgical procedure under ether general anaesthesia consumes approximately 50–200 mL of liquid ether, depending on duration, technique (open-drop vs. drawover vaporiser — drawover uses less), and patient size.³³ The drawover technique with a properly functioning vaporiser uses the lower end of this range; the open-drop method (dripping ether onto gauze) wastes ether through evaporation and uses the upper end.

If NZ performs 100–500 general anaesthetics per year under ether (after maximising regional anaesthesia, ketamine, and local anaesthesia for all possible cases), annual ether consumption is approximately 10–100 litres. This is small-scale chemistry — a single chemist with standard laboratory equipment can produce 5–10 litres per day of purified ether. Even a conservative, quality-focused production programme of one batch per week could meet national demand.³⁴

Ethanol requirement: Approximately 1.2–1.5 litres of 95% ethanol per litre of ether produced (theoretical yield is approximately 0.54 litres ether per litre of ethanol; practical yield 40–60% of theoretical due to side reactions and losses). Annual ethanol requirement for ether production: 15–150 litres. This is negligible compared to NZ’s ethanol production capacity and its ethanol requirements for antiseptic use (Doc #51 — hundreds to thousands of litres per year).³⁵

---

4. ETHER ANAESTHESIA IN PRACTICE

4.1 Administration equipment

Drawover vaporiser (EMO type): The Epstein-Macintosh-Oxford (EMO) drawover vaporiser was specifically designed for ether anaesthesia in low-resource and field settings. It consists of a metal chamber containing ether-soaked wicks, with an inlet and outlet connected to the breathing circuit. As the patient inspires, air is drawn over the wicks, picking up ether vapour. A control lever adjusts the proportion of air that passes over the wick (varying the delivered concentration). A water jacket provides thermal buffering to stabilise output despite ambient temperature changes.³⁶

The EMO is a mechanical device with no electronic components. It can be manufactured by a competent metal workshop (Doc #91) from specifications that are published and freely available. Materials required: sheet steel or brass for the chamber (NZ Steel produces sheet steel at Glenbrook; brass requires copper from recycled stock and zinc — both finite without mining restart), copper or brass tubing for gas pathways (drawn from existing NZ copper stock or recycled electrical cable — Doc #70), textile wicking material (cotton or wool — NZ-produced wool is suitable), a metal water jacket, and a simple lever mechanism. No exotic materials. No precision electronics. A skilled machinist could fabricate one in 1–3 weeks.³⁷

Open-drop method: The simplest possible technique — liquid ether is dripped from a bottle onto a multilayer gauze mask (Schimmelbusch mask) held over the patient’s face. The patient breathes through the gauze, inhaling ether vapour mixed with air. Concentration control is crude (faster drip rate = deeper anaesthesia) and depends entirely on the skill of the anaesthetist. Ether is wasted through evaporation into the room air. Operating room staff are exposed to ether vapour (headache, nausea, potential chronic health effects). This method should be considered a last resort when no drawover vaporiser is available — not the standard technique.³⁸

Modified existing anaesthetic machines: It is technically possible to fill a modern vaporiser with ether, but this is hazardous and should not be done. Modern vaporisers are calibrated for agents with different vapour pressures and potencies than ether. An isoflurane vaporiser filled with ether would deliver unpredictable and potentially lethal concentrations. If existing anaesthetic machines are to be used for ether, a dedicated drawover unit must be incorporated into the circuit, bypassing the machine’s vaporiser. This requires anaesthetic engineering expertise.³⁹

4.2 Ether anaesthesia technique

Ether anaesthesia differs fundamentally from modern volatile anaesthesia in tempo and clinical management. NZ anaesthetists will need to unlearn some habits and learn others.

Induction: Ether has a pungent, irritating odour that causes breath-holding, coughing, and laryngospasm at high concentrations. Induction must begin with low concentrations, gradually increased over 10–15 minutes as the patient progresses through the stages of anaesthesia described by Guedel (1920):⁴⁰

• Stage I (Analgesia): Patient conscious but experiences analgesia and altered awareness. Duration: 1–3 minutes.
• Stage II (Excitement): Patient unconscious but experiences involuntary movements, irregular breathing, possible vomiting, dilated pupils. This is the dangerous stage — the patient may thrash, vomit and aspirate, or develop laryngospasm. The anaesthetist must move through this stage as quickly as possible while avoiding abrupt high concentrations that worsen excitement. Duration: 2–5 minutes.
• Stage III (Surgical anaesthesia): Patient unconscious, muscles relaxed, breathing regular. Divided into four planes of increasing depth. Most surgery is performed at Plane II–III. Duration: maintained as long as needed.
• Stage IV (Medullary paralysis): Overdose. Respiratory arrest, cardiovascular collapse, death. Must be avoided.

Key differences from modern practice that anaesthetists must learn:

1. Patience. Modern induction with propofol takes 30 seconds. Ether induction takes 10–15 minutes. Rushing induction by increasing concentration too quickly produces Stage II excitement and is dangerous.
2. Spontaneous respiration. Ether, unlike modern agents at surgical depth, usually maintains spontaneous breathing. Mechanical ventilation is possible but not routinely needed. This is an advantage in settings where ventilators may not be available.
3. Analgesia. Ether provides significant analgesia (pain relief) at surgical depth — more than sevoflurane or isoflurane. This reduces supplemental opioid requirements.
4. No electrocautery. Ether vapour is flammable at concentrations above 1.9% in air and explosive at higher concentrations. Electrocautery, diathermy, and any electrical spark source must be excluded from the theatre while ether is in use. This changes surgical technique — haemostasis must be achieved by ligation, pressure, or clamp, not cautery. Surgeons accustomed to liberal cautery use will need to adapt.⁴¹
5. Recovery. Ether recovery is slow (30–60+ minutes) with high rates of nausea and vomiting (40–70% of patients). Post-anaesthetic care must account for this — lateral positioning, suction availability, extended recovery observation.⁴²

4.3 Ether’s advantages in resource-limited settings

Despite its disadvantages, ether has properties that make it well-suited to recovery-era conditions:

• Wide safety margin. The ratio of lethal dose to effective dose is wider for ether than for any modern volatile agent. This makes ether more forgiving of imprecise concentration delivery — important when using a drawover vaporiser rather than a calibrated modern vaporiser.⁴³
• Respiratory stability. Patients maintain spontaneous breathing at surgical anaesthetic depth. This reduces dependence on mechanical ventilation and allows anaesthesia to be provided without compressed gas supplies.
• Cardiovascular stability. Ether produces less myocardial depression and hypotension than modern volatile agents at equivalent anaesthetic depth.⁴⁴
• Analgesic effect. Reduces supplemental analgesic requirements, conserving opioid stocks.
• No specialised equipment required. Can be administered with a drawover vaporiser (fabricable in NZ), or in extremis with open-drop gauze technique. No anaesthetic machine, compressed gas supply, or electricity required for the anaesthetic itself — though monitoring equipment obviously requires power.

4.4 Ether’s disadvantages — stated honestly

• Flammability and explosion risk. This is the most dangerous property. Theatre design and workflow must change to eliminate ignition sources. Operations that depend on electrocautery (some vascular surgery, extensive soft tissue surgery where cautery provides essential haemostasis) become substantially more difficult without cautery. This is a real loss of surgical capability, not a minor inconvenience.⁴⁵
• Slow induction and recovery. Operating theatre throughput decreases. In a mass casualty scenario, slow induction is a significant disadvantage.
• Nausea and vomiting. Affects patient comfort and recovery. Aspiration of vomitus is a real risk, particularly during the excitement stage and during recovery. Anti-emetic drugs (ondansetron) are finite.
• Staff exposure. Operating room staff are exposed to ether vapour, particularly with the open-drop technique. Chronic ether exposure causes headache, nausea, and potential liver damage. Adequate theatre ventilation is essential — under baseline scenario, theatre ventilation systems operate on grid power.⁴⁶
• Peroxide risk. Improperly stored ether forms explosive peroxides. This is a storage and handling hazard, not a clinical one, but it demands disciplined quality control (Section 3.3).
• Retraining requirement. NZ’s anaesthetic workforce has no current clinical experience with ether. Retraining carries risk during the learning curve — the first ether anaesthetics will have higher complication rates than the hundredth.

---

5. REGIONAL AND LOCAL ANAESTHESIA: EXTENDING CAPABILITY

5.1 The strategic role of regional anaesthesia

Regional anaesthesia — spinal, epidural, and peripheral nerve blocks — is the most important strategy for reducing NZ’s dependence on general anaesthetic agents. Every operation performed under spinal or nerve block is an operation that consumes no volatile agent, no propofol, no muscle relaxant, and minimal local anaesthetic (especially for spinal).

Current NZ practice: NZ anaesthetists are generally well-trained in regional techniques, though practice varies. Spinal anaesthesia is routine for caesarean sections and some lower limb surgery. Peripheral nerve blocks are increasingly common, driven by ultrasound-guided technique. However, many operations currently performed under general anaesthesia could be performed under regional — the barrier in peacetime is convenience and patient preference, not technical impossibility.

Post-event shift: Under conservation protocols, regional anaesthesia should become the default for all operations below the mid-thorax (approximately T6 dermatome level). General anaesthesia should be reserved for operations above this level, for patients with contraindications to regional anaesthesia, and for paediatric cases where cooperation is not achievable.

5.2 Spinal anaesthesia — maximising this resource

Spinal anaesthesia deserves particular emphasis because it consumes the least local anaesthetic per case and covers the widest range of surgical procedures of any regional technique.

What spinal anaesthesia requires:

• 1.5–3.5 mL of local anaesthetic (bupivacaine 0.5% heavy is the NZ standard)⁴⁷
• A spinal needle (typically 25–27 gauge, pencil-point). Spinal needles are metal, autoclavable, and reusable. NZ hospitals hold stocks of disposable spinal needles that can be resterilised (Doc #117). When disposable stocks are exhausted, reusable spinal needles (which were standard before the disposable era) can be fabricated by NZ’s instrument workshops — they are a hollow metal tube with a stylet, not a complex device.
• Antiseptic for skin preparation (ethanol — locally producible)
• A sterile environment (skin prep and aseptic technique — no operating theatre required; spinal can be performed in any clean room)

Extending bupivacaine duration through spinal-only reservation: If NZ holds approximately 5,000–10,000 ampoules of bupivacaine 0.5% (4 mL each = 20,000–40,000 mL total), and spinal anaesthesia uses 2–3 mL per case, the stock supports approximately 6,600–20,000 spinal anaesthetics. At 1,000–3,000 spinal anaesthetics per year (post-event volume), this represents 3–20 years of spinal anaesthesia capability.⁴⁸ This is achievable only if bupivacaine is strictly reserved for spinal and epidural use and not consumed for less efficient applications (field blocks, wound infiltration) that can be served by lidocaine.

When bupivacaine is exhausted: Lidocaine can be used for spinal anaesthesia (5% heavy lidocaine was the standard spinal agent before bupivacaine). Duration is shorter (60–90 minutes vs. 2–3 hours for bupivacaine) but adequate for many procedures. Lidocaine spinal carries a historical concern about transient neurological symptoms (TNS) — self-limiting radicular pain in the lower limbs — at a rate of approximately 10–30% with lidocaine vs. less than 1% with bupivacaine.⁴⁹ This is a real but manageable side effect — not a contraindication when the alternative is general anaesthesia with a finite agent.

5.3 When local anaesthetic stocks are exhausted [Phase 3–5]

This is the hardest section. When all synthetic local anaesthetic drugs (lidocaine, bupivacaine, ropivacaine) are exhausted — projected at 3–10 years post-event depending on conservation success — NZ has no locally producible equivalent of comparable quality. Procaine (Novocaine) can theoretically be synthesised from coal tar derivatives (Doc #119, Section 3.6), but this depends on industrial organic chemistry infrastructure that is years to decades away.

Options without local anaesthetic drugs:

• General anaesthesia (ether or ketamine) for all surgical procedures, including those that would normally be done under local. This uses more resources per case, increases risk, and slows throughput.
• Cryoanaesthesia (ice/cold application) for superficial procedures. Effective for brief surface numbness. Inadequate for anything requiring deep tissue anaesthesia.
• Ethanol nerve blocks (destructive — see Doc #51, Section 6.4). Only for amputations or terminal pain.
• Ketamine sub-anaesthetic analgesia — low-dose ketamine (0.1–0.3 mg/kg IV) provides significant analgesia without full anaesthesia. Combined with local wound infiltration using dilute ethanol or cold, may be adequate for minor procedures.
• Kawakawa (Piper excelsum) preparations. Kawakawa leaves contain myristicin and dihydrokawain, compounds with mild analgesic and anti-inflammatory properties.⁵⁰ The analgesic effect is modest — equivalent to a modest dose of paracetamol at best — and not sufficient for surgical anaesthesia. However, kawakawa preparations (poultice or oral) have genuine value for post-operative pain management as a supplement to scarce pharmaceutical analgesics, particularly when paracetamol and ibuprofen stocks are rationed.
• Psychological pain management. Anxiety and distress amplify pain perception; psychological preparation, structured spiritual or social support, and the presence of trusted family members reduce it — this is well-established in pain neuroscience.⁵¹ Structured psychological interventions before and during procedures measurably reduce pain perception and analgesic requirements. Karakia (ritual incantation) and whanau support provide an established, practised framework for delivering this psychological intervention in Maori patients, and analogous approaches (chaplaincy, family presence, guided relaxation) should be standard for all patients undergoing procedures with limited pharmacological pain control.
• Conscious surgery with sedation and restraint — the pre-1846 reality. Ethanol or opioid sedation, physical restraint, speed as the surgeon’s primary anaesthetic. Patient suffering is severe and surgical precision is compromised by patient movement, but this may be the only option for minor procedures when all other agents are exhausted. It should not be used for major surgery — the physiological stress of unanaesthetised major surgery causes shock and death.⁵²

Honest assessment: The loss of local anaesthetic capability is one of the most significant medical regressions NZ will face. There is no adequate substitute. The strategy is to extend local anaesthetic stocks as long as possible (3–10 years through spinal-only reservation and strict rationing), bridge with ketamine and ether for general anaesthesia, and hope that either domestic chemical production or trade provides synthetic local anaesthetics before stocks are fully exhausted.

---

CRITICAL UNCERTAINTIES

Uncertainty	Impact if wrong	Resolution method
Actual NZ anaesthetic agent stock levels	Stocks may be larger or smaller than estimated by a factor of 2. If smaller, transition timeline compresses	National inventory (Action 1) — highest priority information need
Sulfuric acid production timeline (Doc #113)	If sulfuric acid is delayed beyond 12–18 months, ether production is delayed correspondingly	Accelerate Doc #113 programme. Investigate phosphoric acid alternative. Secure existing sulfuric acid stocks
Quality of locally produced ether	Impure ether is dangerous. If quality control fails, ether production does more harm than good	Rigorous QC protocols (Section 3.3). Clinical validation with modern backup available (Action 10). Reject substandard batches without exception
Ether retraining success	NZ anaesthetists have never used ether clinically. Learning curve may produce complications	Begin training immediately (Action 5). Use simulation first. Start clinical use on simple, low-risk cases with modern backup. Accept that the first year will have higher complication rates
Ketamine veterinary stock volume	If larger than estimated, bridge period extends. If smaller, ether production becomes more urgent	Inventory (Action 3)
Bupivacaine stock and spinal-only conservation	If strict reservation is not enforced, bupivacaine depletes much faster than projected	Governance: central allocation through National Pharmaceutical Triage Authority (Doc #116). Clear protocols. Clinical leadership
Chloroform as backup general anaesthetic	Chloroform has a narrower safety margin than ether and hepatotoxicity risk. If ether production fails, chloroform may be the only alternative	Develop chloroform capability in parallel (Doc #119) but maintain ether as primary. Chloroform should remain second-line
Patient acceptance of ether anaesthesia	Ether is unpleasant — slow induction, nausea, vomiting. Patients may refuse. Some may request surgery without anaesthesia rather than undergo ether	Patient communication. Acknowledge that ether is worse than modern anaesthesia but explain it is safe. Ketamine may be preferred for patients with severe ether-phobia, if stocks allow
Procaine synthesis timeline	If coal tar chemistry develops faster than expected, locally produced local anaesthetic could become available within 5–10 years. If not, local anaesthetic capability is lost permanently until trade provides it	Monitor Doc #119 industrial chemistry development. Prioritise procaine precursor production if coal tar distillation comes online
Soda lime depletion	Exhaustion of soda lime stocks forces earlier transition from circle circuits to drawover systems, reducing conservation benefit for remaining volatile agents	Include soda lime in the national anaesthetic inventory. Investigate local soda lime production (calcium hydroxide + sodium hydroxide — both locally producible in principle)

---

CROSS-REFERENCES

Document	Relationship
Doc #4 — Pharmaceutical and Medical Supply Management	Logistics framework for controlled distribution of anaesthetic agents as part of the national pharmaceutical supply
Doc #91 — Machine Shop Operations	Fabrication of drawover vaporisers, spinal needles, and other anaesthetic equipment
Doc #113 — Sulfuric Acid Production	Upstream dependency for ether synthesis. Without sulfuric acid, ether production cannot proceed
Doc #116 — Pharmaceutical Rationing	Anaesthetic agents rationed within the national pharmaceutical triage framework. Ketamine and opioid allocation governed by Triage Authority
Doc #117 — Surgical Consumable Conservation	Companion document covering all other surgical consumables. Section 6 of Doc #117 overlaps with this document; this document (Doc #118) provides the deeper technical detail on anaesthetic alternatives
Doc #119 — Local Pharmaceutical Production	Ether production (Section 2.4), chloroform (Section 3.3), and procaine (Section 3.6) covered at overview level. This document (Doc #118) provides operational detail for the anaesthesia transition programme
Doc #122 — Mental Health	Psychological aspects of pain management, patient anxiety about anaesthetic regression, and staff psychological impact of providing care with degraded tools
Doc #123 — Midwifery and Maternity	Caesarean section anaesthesia is a critical application for spinal anaesthesia conservation. Obstetric anaesthesia planning must coordinate with this document
Doc #059 — Biodiesel and Alcohol Production	Ethanol production infrastructure shared between fuel, antiseptic, and ether production programmes
Doc #067 — Hydroelectric Maintenance	Grid reliability determines continued operation of operating theatre infrastructure (ventilation, monitoring, lighting, suction)

---

FOOTNOTES

---

1. NZ’s pharmaceutical import dependence is documented in Doc #116 (Pharmaceutical Rationing) and Doc #119 (Local Pharmaceutical Production). NZ imports essentially all anaesthetic agents. The only NZ-based pharmaceutical manufacturers (Douglas Pharmaceuticals, AFT Pharmaceuticals, both Auckland) produce finished dose forms from imported active pharmaceutical ingredients and do not synthesise volatile anaesthetics or local anaesthetic APIs. See PHARMAC Annual Reports, https://www.pharmac.govt.nz/↩︎

2. Anaesthesia-related mortality in modern NZ practice is approximately 1 in 100,000–200,000 anaesthetics, consistent with international data from developed countries. See: Bainbridge D, et al. “Perioperative and anaesthetic-related mortality in developed and developing countries: a systematic review and meta-analysis.” Lancet 380(9847):1075–1081, 2012. Historical ether anaesthesia mortality was approximately 1 in 10,000–15,000 — roughly a 10-fold increase over modern rates. Source: Dripps RD, Lamont A, Eckenhoff JE. “The Role of Anesthesia in Surgical Mortality.” JAMA 178(3):261–266, 1961.↩︎

3. NZ chemistry workforce: NZ has approximately 2,000–3,000 professionally trained chemists and chemical technicians across university, industrial, and government laboratories (estimate based on RSNZ membership data and NZ Qualifications Authority graduate figures). However, many of these are analytical, environmental, or research chemists without production chemistry experience. The synthetic chemistry skills required for ether production are basic but the quality control discipline is demanding. Competition for chemistry workforce from sulfuric acid production (Doc #113), pharmaceutical production (Doc #119), water treatment, and agricultural chemistry must be managed.↩︎

4. NZ surgical centre count: NZ’s public hospital system operates approximately 20–25 sites with dedicated surgical capability, ranging from major tertiary hospitals (Auckland, Wellington, Christchurch) to smaller regional hospitals with limited surgical capacity. Private surgical facilities add approximately 40–60 additional theatres but may not be operational post-event. The 20–30 vaporiser target covers all public surgical sites plus selected rural and private facilities likely to remain in use. Source: Te Whatu Ora / Health NZ facility data.↩︎

5. Australian and New Zealand College of Anaesthetists (ANZCA) workforce data. https://www.anzca.edu.au/ — ANZCA reports approximately 2,000+ Fellows practising in NZ and Australia combined. NZ’s share is approximately 500–600 specialist anaesthetists. Exact numbers fluctuate with recruitment and retirement. GP anaesthetists are registered separately through the Royal New Zealand College of General Practitioners and provide rural anaesthesia services in smaller hospitals.↩︎

6. NZ emergency surgical mortality estimate: NZ performs approximately 30,000–50,000 emergency or urgent surgical procedures per year (Ministry of Health surgical volume data). Conditions requiring emergency surgery — appendicitis (mortality 1–5% if untreated, rising to 20–30% with perforation), strangulated hernia (mortality 10–20% without reduction), obstructed labour requiring caesarean (maternal mortality 1–5% without surgical delivery) — would collectively cause an estimated 2,000–5,000 additional deaths per year if surgical anaesthesia were unavailable. This estimate is approximate and based on historical pre-surgical-era mortality for these conditions.↩︎

7. Australian and New Zealand College of Anaesthetists (ANZCA) workforce data. https://www.anzca.edu.au/ — ANZCA reports approximately 2,000+ Fellows practising in NZ and Australia combined. NZ’s share is approximately 500–600 specialist anaesthetists. Exact numbers fluctuate with recruitment and retirement. GP anaesthetists are registered separately through the Royal New Zealand College of General Practitioners and provide rural anaesthesia services in smaller hospitals.↩︎

8. Countryside Anaesthesia — GP anaesthetists in NZ. NZ’s GP anaesthesia model, where specially trained general practitioners provide anaesthesia services in rural hospitals, is relatively unusual internationally and provides anaesthetic coverage to communities that would otherwise require patient transfer to distant centres. Approximately 100–200 GP anaesthetists practise in NZ. This workforce is valuable under recovery conditions because it is distributed geographically, reducing dependence on centralised specialist services.↩︎

9. Ether was progressively replaced in NZ clinical practice during the 1960s–1980s, first by halothane (introduced 1956, widely adopted in NZ by the 1960s), then by enflurane (1970s) and isoflurane (1980s), and finally by sevoflurane (1990s–2000s). By the 1990s, ether was no longer used clinically in NZ hospitals. Source: General medical history of anaesthesia; specific NZ transition timeline based on ANZCA historical records and NZ anaesthetic practice patterns.↩︎

10. NZ Ministry of Health surgical volume data. NZ performs approximately 200,000–250,000 surgical procedures requiring anaesthesia per year across all public and private facilities. The number of operating theatres in the public system is approximately 80–100, with additional private facility theatres. Exact figures require verification from Te Whatu Ora / Health NZ.↩︎

11. NZ Ministry of Health surgical volume data. NZ performs approximately 200,000–250,000 surgical procedures requiring anaesthesia per year across all public and private facilities. The number of operating theatres in the public system is approximately 80–100, with additional private facility theatres. Exact figures require verification from Te Whatu Ora / Health NZ.↩︎

12. Baum JA, Aitkenhead AR. “Low-flow anaesthesia.” Anaesthesia 50(Suppl):37–44, 1995. Also: Brattwall M, et al. “Brief review: Theory and practice of minimal fresh gas flow anesthesia.” Canadian Journal of Anesthesia 59(8):785–797, 2012. Low-flow technique (fresh gas flow 0.5 L/min vs. standard 2–6 L/min) reduces volatile agent consumption by 50–75%. The technique is well-established and taught in NZ anaesthetic training but not universally practised because, under normal supply conditions, the additional vigilance required is not justified by cost savings.↩︎

13. Baum JA, Aitkenhead AR. “Low-flow anaesthesia.” Anaesthesia 50(Suppl):37–44, 1995. Also: Brattwall M, et al. “Brief review: Theory and practice of minimal fresh gas flow anesthesia.” Canadian Journal of Anesthesia 59(8):785–797, 2012. Low-flow technique (fresh gas flow 0.5 L/min vs. standard 2–6 L/min) reduces volatile agent consumption by 50–75%. The technique is well-established and taught in NZ anaesthetic training but not universally practised because, under normal supply conditions, the additional vigilance required is not justified by cost savings.↩︎

14. Hadzic A. Hadzic’s Textbook of Regional Anesthesia and Acute Pain Management. McGraw-Hill, 2nd edition, 2017. Standard reference for regional anaesthesia techniques, indications, and contraindications. The procedures listed as suitable for spinal anaesthesia are well-established in NZ anaesthetic practice.↩︎

15. Bupivacaine 0.5% heavy (hyperbaric) is the standard agent for spinal anaesthesia in NZ. Typical dose: 2–3 mL (10–15 mg) for lower abdominal and lower limb surgery; 1.5–2 mL (7.5–10 mg) for perineal surgery. Stock estimates are based on hospital pharmacy procurement patterns and distributor pipeline data — exact figures require the national inventory. The projection of 3–20 years of spinal capability is arithmetic: total stock volume divided by average volume per case divided by annual case volume, with the wide range reflecting uncertainty in all three variables.↩︎

16. Marhofer P, et al. “Ultrasonographic guidance in regional anaesthesia.” British Journal of Anaesthesia 94(1):7–17, 2005. Ultrasound guidance improves block success rates and reduces local anaesthetic volume requirements by enabling more precise needle placement. NZ hospitals have ultrasound machines in most anaesthetic departments; these continue to function under baseline scenario (grid available).↩︎

17. Ketamine is classified as a Class C controlled drug in NZ under the Misuse of Drugs Act 1975. It is widely used in veterinary anaesthesia — virtually every veterinary practice in NZ stocks ketamine for animal sedation and anaesthesia. The veterinary formulation (typically 100 mg/mL ketamine hydrochloride solution) is chemically identical to human formulations. Source: NZ Veterinary Association practice guidelines; Misuse of Drugs Act 1975.↩︎

18. The chemical identity of veterinary and human ketamine is addressed in Doc #124, Section 6 (Veterinary Pharmaceutical Integration). The active ingredient is the same molecule (ketamine hydrochloride); the distinction is regulatory labelling, not chemistry. Excipient compatibility should be confirmed per product, but standard veterinary ketamine solutions (aqueous, preserved with benzethonium chloride or similar) are generally suitable for human use.↩︎

19. Green SM, Roback MG, Kennedy RM, Krauss B. “Clinical Practice Guideline for Emergency Department Ketamine Dissociative Sedation: 2011 Update.” Annals of Emergency Medicine 57(5):449–461, 2011. Emergence phenomena (hallucinations, dysphoria, agitation) occur in approximately 10–30% of adults; much less common in children. Co-administration of midazolam 0.03–0.05 mg/kg reduces incidence to approximately 5%.↩︎

20. The traditional teaching that ketamine raises intracranial pressure (ICP) and is contraindicated in head injury has been questioned by more recent evidence. See: Zeiler FA, et al. “The ketamine effect on ICP in traumatic brain injury.” Neurocritical Care 21(1):163–173, 2014. The effect may be clinically insignificant in patients with controlled ventilation. However, the precautionary principle applies in a resource-limited setting where ICP monitoring may not be available.↩︎

21. Chloroform anaesthesia mortality was historically approximately 1 in 3,000 administrations, compared to approximately 1 in 15,000 for ether. The therapeutic margin (difference between effective dose and lethal dose) is narrower. Hepatotoxicity (liver damage) from chloroform is well-documented and can be fatal. Source: Sykes WS. Essays on the First Hundred Years of Anaesthesia, 1960. Also: Section 3.3 above.↩︎

22. Diethyl ether synthesis by acid-catalysed dehydration of ethanol was first described by Valerius Cordus in 1540 and has been performed continuously since. It is standard introductory organic chemistry. The reaction mechanism (protonation of ethanol by sulfuric acid, nucleophilic attack by a second ethanol molecule, elimination of water) is well-understood. Temperature control at 140°C is critical — below 130°C the reaction is too slow; above 150°C, elimination to ethylene predominates. Source: Any introductory organic chemistry textbook; e.g., Morrison & Boyd, Organic Chemistry; Clayden et al., Organic Chemistry.↩︎

23. NZ ethanol production capacity: NZ has distilling infrastructure for whisky (multiple distilleries in NZ — e.g., Thomson Whisky, Cardrona Distillery), spirits, and bioethanol. Fermentation of any sugar or starch source (grain, sugar beet, molasses, fruit waste, whey) followed by distillation produces 95%+ ethanol. NZ’s dairy industry produces large volumes of whey that can serve as fermentation feedstock. See Doc #059 (Biodiesel and Alcohol Production).↩︎

24. Diethyl ether synthesis by acid-catalysed dehydration of ethanol was first described by Valerius Cordus in 1540 and has been performed continuously since. It is standard introductory organic chemistry. The reaction mechanism (protonation of ethanol by sulfuric acid, nucleophilic attack by a second ethanol molecule, elimination of water) is well-understood. Temperature control at 140°C is critical — below 130°C the reaction is too slow; above 150°C, elimination to ethylene predominates. Source: Any introductory organic chemistry textbook; e.g., Morrison & Boyd, Organic Chemistry; Clayden et al., Organic Chemistry.↩︎

25. Ether purification methods: Standard organic chemistry laboratory technique. Washing sequence (water, sodium hydroxide, water, drying agent, redistillation) is described in: Armarego WLF, Chai CLL. Purification of Laboratory Chemicals, 7th edition, Butterworth-Heinemann, 2012. The specific gravity of pure diethyl ether at 20°C is 0.7134 g/mL (CRC Handbook of Chemistry and Physics).↩︎

26. Ether peroxide hazards: Organic peroxides formed by autoxidation of ether are friction- and heat-sensitive explosives. Multiple laboratory explosions have been caused by distillation of peroxide-containing ether. Detection: potassium iodide test (starch-iodide paper turns blue in the presence of peroxides) or ferrous thiocyanate test. Prevention: storage with stabiliser (BHT, copper wire), exclusion of air and light, use within shelf life. See: Clark DE. “Peroxides and Peroxide-Forming Compounds.” Chemical Health and Safety 8(5):12–22, 2001.↩︎

27. Ether vapour is 2.55 times denser than air (molecular weight 74.12 vs. air ~29). It accumulates at floor level and can travel significant distances along floors and through drains to reach ignition sources. Flash point: -45°C. Autoignition temperature: 160°C. Explosive limits in air: 1.9–36% by volume. These physical properties are from standard chemical safety data (e.g., NIOSH, PubChem).↩︎

28. Ether peroxide hazards: Organic peroxides formed by autoxidation of ether are friction- and heat-sensitive explosives. Multiple laboratory explosions have been caused by distillation of peroxide-containing ether. Detection: potassium iodide test (starch-iodide paper turns blue in the presence of peroxides) or ferrous thiocyanate test. Prevention: storage with stabiliser (BHT, copper wire), exclusion of air and light, use within shelf life. See: Clark DE. “Peroxides and Peroxide-Forming Compounds.” Chemical Health and Safety 8(5):12–22, 2001.↩︎

29. Ether purification methods: Standard organic chemistry laboratory technique. Washing sequence (water, sodium hydroxide, water, drying agent, redistillation) is described in: Armarego WLF, Chai CLL. Purification of Laboratory Chemicals, 7th edition, Butterworth-Heinemann, 2012. The specific gravity of pure diethyl ether at 20°C is 0.7134 g/mL (CRC Handbook of Chemistry and Physics).↩︎

30. The temptation to release substandard product under supply pressure is the most serious quality risk in any wartime or crisis pharmaceutical production programme. Historical precedent: early penicillin production in WWII had significant quality variation between batches, with clinical consequences. The principle must be: reject and re-process, not release and hope. Source: General pharmaceutical production quality principle; see also Doc #119, Section 3.4 on penicillin quality control.↩︎

31. Sulfuric acid is not consumed in ether synthesis — it acts as a proton donor catalyst and is regenerated in the reaction cycle. A small quantity (relative to the ethanol) is sufficient, though some is lost through side reactions and carry-over into the product (removed by washing). Practical requirement: approximately 0.3–0.5 litres of concentrated sulfuric acid per 10 litres of ether produced, assuming efficient recovery. Source: Standard organic chemistry; reaction stoichiometry.↩︎

32. Phosphoric acid (H₃PO₄) can catalyse ethanol dehydration to ether, though at somewhat lower efficiency and at higher temperatures (180–200°C vs. 140°C for sulfuric acid). NZ’s phosphoric acid stocks exist primarily in the fertiliser industry (superphosphate production at Ravensdown and Ballance Agri-Nutrients plants) and in food processing. This is a documented alternative route: Butt JB. Reaction Kinetics and Reactor Design, CRC Press, 2000.↩︎

33. Ether consumption per anaesthetic: Estimates from WHO Guidelines for Essential Drugs and Medicines Policy, and from historical anaesthetic practice data. Open-drop technique uses 100–200 mL per hour; drawover vaporiser uses 50–100 mL per hour. Duration of average surgical anaesthetic: 30–90 minutes. Total consumption per case: 50–200 mL depending on technique and duration.↩︎

34. Production rate estimate: A laboratory-scale ether synthesis using a 2-litre round-bottom flask can produce approximately 500 mL–1 litre of purified ether per batch (2–4 hours including distillation and purification). A dedicated chemist running 2–3 batches per day can produce 1–3 litres per day. At 3 litres per day, 5 days per week, annual production capacity is approximately 750 litres — far exceeding projected demand. Even a conservative once-per-week production schedule yields approximately 50–150 litres per year. This calculation is based on standard laboratory organic chemistry production rates.↩︎

35. NZ ethanol production capacity: NZ has distilling infrastructure for whisky (multiple distilleries in NZ — e.g., Thomson Whisky, Cardrona Distillery), spirits, and bioethanol. Fermentation of any sugar or starch source (grain, sugar beet, molasses, fruit waste, whey) followed by distillation produces 95%+ ethanol. NZ’s dairy industry produces large volumes of whey that can serve as fermentation feedstock. See Doc #059 (Biodiesel and Alcohol Production).↩︎

36. The EMO (Epstein-Macintosh-Oxford) drawover vaporiser was developed in the 1950s by Ninewells Hospital anaesthetist HG Epstein, Sir Robert Macintosh (Oxford University), and the Oxford Vaporiser design team. It was specifically designed for use in low-resource settings and with ether. The design features temperature compensation (water jacket), adjustable concentration control (mechanical lever), and compatibility with drawover (spontaneous ventilation) circuits. Specifications published in: Macintosh RR, Mushin WW, Epstein HG. Physics for the Anaesthetist. Blackwell Scientific, 1963; and various WHO/WFSA technical publications.↩︎

37. EMO vaporiser fabrication: The EMO is a mechanical device requiring sheet metal work (chamber, water jacket), brass or copper tubing (gas pathways), a textile wick, and a simple lever/valve mechanism. No electronic components. A competent metalworker with access to a lathe, soldering equipment, and sheet metal tools can fabricate one. Estimated fabrication time: 1–3 weeks per unit for a skilled workshop. Source: Published EMO technical drawings and specifications; assessment based on Doc #91 (Machine Shop Operations) capability.↩︎

38. The open-drop technique was first used by William Morton in the first public demonstration of ether anaesthesia (Massachusetts General Hospital, October 16, 1846) and remained the primary method of ether administration until drawover and plenum vaporisers were developed. The Schimmelbusch mask (wire frame covered with gauze) was the standard open-drop apparatus from the 1890s. Source: Sykes WS. Essays on the First Hundred Years of Anaesthesia, 1960.↩︎

39. Filling a modern agent-specific vaporiser with ether: Modern vaporisers are calibrated for the specific vapour pressure and potency (MAC value) of one agent. Ether has a much higher vapour pressure and lower potency than sevoflurane or isoflurane. An isoflurane vaporiser set to deliver “1%” would deliver an unpredictable and potentially much higher concentration of ether vapour, because the vaporiser’s internal calibration does not match ether’s physical properties. The risk of overdose is substantial. Source: Dorsch JA, Dorsch SE. Understanding Anesthesia Equipment, Lippincott Williams & Wilkins, 5th edition, 2008.↩︎

40. Guedel AE. Inhalation Anesthesia: A Fundamental Guide. Macmillan, 1937. Guedel’s classification of the stages of ether anaesthesia remains the most widely taught framework for understanding the clinical progression of inhalation anaesthesia. While modern agents pass through these stages so rapidly that they are clinically irrelevant, ether’s slow induction makes them critically important.↩︎

41. Electrocautery prohibition during ether anaesthesia: Ether vapour is flammable at concentrations above 1.9% in air. Electrocautery and diathermy devices produce sparks. The combination is explosive. Multiple operating room fires and explosions occurred during the ether era. The prohibition is absolute — no exceptions. Modern surgery has become heavily dependent on electrocautery for haemostasis, and the loss of this tool is a significant surgical capability regression. Source: Macdonald AG. “A Short History of Fires and Explosions Caused by Anaesthetic Agents.” British Journal of Anaesthesia 73(6):847–856, 1994.↩︎

42. Post-operative nausea and vomiting (PONV) with ether anaesthesia: Historical data consistently reports PONV rates of 40–70% after ether anaesthesia, compared to 20–30% after modern volatile agents and 10–20% after propofol-based anaesthesia. Source: Palazzo M, Evans R. “Logistic regression analysis of fixed patient factors for postoperative sickness: a model for risk assessment.” British Journal of Anaesthesia 70(2):135–140, 1993 (modern data for comparison); historical ether PONV data from mid-20th century anaesthetic literature.↩︎

43. Ether safety margin: MAC (minimum alveolar concentration) of ether is approximately 1.9%; the approximate lethal concentration is 5–6% in controlled animal studies. This gives a therapeutic ratio of approximately 3:1. Compare sevoflurane (MAC ~2%, lethal concentration poorly defined but therapeutic ratio narrower in practice due to cardiovascular depression). Ether’s wider safety margin was one reason it remained in use long after chloroform (therapeutic ratio approximately 1.5–2:1) was recognised as more dangerous. Source: Miller RD. Miller’s Anesthesia, Elsevier, 9th edition, 2020 (modern reference); Dripps RD et al., JAMA 1961 (historical data).↩︎

44. Ether safety margin: MAC (minimum alveolar concentration) of ether is approximately 1.9%; the approximate lethal concentration is 5–6% in controlled animal studies. This gives a therapeutic ratio of approximately 3:1. Compare sevoflurane (MAC ~2%, lethal concentration poorly defined but therapeutic ratio narrower in practice due to cardiovascular depression). Ether’s wider safety margin was one reason it remained in use long after chloroform (therapeutic ratio approximately 1.5–2:1) was recognised as more dangerous. Source: Miller RD. Miller’s Anesthesia, Elsevier, 9th edition, 2020 (modern reference); Dripps RD et al., JAMA 1961 (historical data).↩︎

45. Electrocautery prohibition during ether anaesthesia: Ether vapour is flammable at concentrations above 1.9% in air. Electrocautery and diathermy devices produce sparks. The combination is explosive. Multiple operating room fires and explosions occurred during the ether era. The prohibition is absolute — no exceptions. Modern surgery has become heavily dependent on electrocautery for haemostasis, and the loss of this tool is a significant surgical capability regression. Source: Macdonald AG. “A Short History of Fires and Explosions Caused by Anaesthetic Agents.” British Journal of Anaesthesia 73(6):847–856, 1994.↩︎

46. Chronic occupational ether exposure: Operating room staff exposed to ambient ether vapour experienced headache, fatigue, nausea, and potential hepatic effects. Adequate theatre ventilation (baseline scenario: HVAC on grid power) substantially reduces exposure. The transition from ether to halothane in the 1960s–70s was partly motivated by reduced staff exposure, though halothane subsequently proved to have its own hepatotoxicity issues. Source: Occupational health literature from the pre-halothane era; NIOSH occupational exposure limits for diethyl ether (400 ppm TWA).↩︎

47. Bupivacaine 0.5% heavy (hyperbaric) is the standard agent for spinal anaesthesia in NZ. Typical dose: 2–3 mL (10–15 mg) for lower abdominal and lower limb surgery; 1.5–2 mL (7.5–10 mg) for perineal surgery. Stock estimates are based on hospital pharmacy procurement patterns and distributor pipeline data — exact figures require the national inventory. The projection of 3–20 years of spinal capability is arithmetic: total stock volume divided by average volume per case divided by annual case volume, with the wide range reflecting uncertainty in all three variables.↩︎

48. Bupivacaine 0.5% heavy (hyperbaric) is the standard agent for spinal anaesthesia in NZ. Typical dose: 2–3 mL (10–15 mg) for lower abdominal and lower limb surgery; 1.5–2 mL (7.5–10 mg) for perineal surgery. Stock estimates are based on hospital pharmacy procurement patterns and distributor pipeline data — exact figures require the national inventory. The projection of 3–20 years of spinal capability is arithmetic: total stock volume divided by average volume per case divided by annual case volume, with the wide range reflecting uncertainty in all three variables.↩︎

49. Transient neurological symptoms (TNS) after lidocaine spinal anaesthesia: Zaric D, et al. “Transient Neurological Symptoms (TNS) following spinal anaesthesia with lidocaine versus other local anaesthetics.” Cochrane Database of Systematic Reviews, 2005. TNS (self-limiting radicular pain and dysaesthesia in the lower limbs, onset within 24 hours, resolution within 72 hours) occurs in approximately 10–30% of patients receiving lidocaine spinal anaesthesia vs. less than 1% for bupivacaine. The symptoms are unpleasant but not dangerous and resolve completely. Under rationing conditions where bupivacaine is exhausted, lidocaine spinal with the known TNS risk is an acceptable alternative.↩︎

50. Kawakawa (Piper excelsum): Traditional Māori use for toothache and wound pain is documented in: Riley M. Māori Healing and Herbal. Viking Sevenseas, 1994. Pharmacological analysis confirms presence of myristicin, dihydrokawain, and other bioactive compounds with mild analgesic and anti-inflammatory properties. The effect is modest — not comparable to synthetic analgesics — but has genuine clinical utility as a supplement.↩︎

51. Psychological modulation of pain perception: The interaction between anxiety, expectation, and pain experience is well-established in pain neuroscience. See: Bushnell MC, Čeko M, Low LA. “Cognitive and emotional control of pain and its disruption in chronic pain.” Nature Reviews Neuroscience 14(7):502–511, 2013. Māori cultural practices of karakia, whānau support, and spiritual preparation for medical procedures provide a structured system for delivering this psychological support. Integration should be guided by Māori practitioners and consistent with tikanga.↩︎

52. Pre-anaesthetic surgical mortality: Before the introduction of ether anaesthesia in 1846, major surgery carried mortality rates of 25–40% from surgical shock alone (distinct from infection), driven by the extreme physiological stress response to uncontrolled pain — catecholamine surge, tachycardia, hypertension, and vasovagal collapse. Minor procedures (abscess drainage, wound debridement, digit amputation) were survivable under restraint and sedation but with significant patient suffering and compromised surgical precision. Source: Pernick MS. A Calculus of Suffering: Pain, Professionalism, and Anesthesia in Nineteenth-Century America. Columbia University Press, 1985.↩︎